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ABSTRACT
Purpose: Calcitonin receptor gene has also a polymorphism which is associated with bone mass density. 
This study evaluates the association between calcitonin receptor AluI (rs1801197) and Taq1 calcitonin 
genes polymorphism with bone density rate. Methods: In this descriptive-analytical study in 2013 in 
southwestern Iran, 200 blood samples, per the Cochran sample size formula, were taken from women 
aged 45 and older. DNA was extracted from the samples using the phenol– chloroform method and the 
genomic fragments in question were proliferated using the polymerase chain reaction (PCR) method. 
Results: The genotypic distribution of polymorphism AluI for TT, TC, and CC genotypes in control group 
was 31.4%, 38.6%, and 30% and in patients 25.4%, 55.4%, and 19.2%, respectively. There was no signifi-
cant difference in polymorphism AluI between patients and control group and no significant association 
was found between this gene and bone density rate (P > 0.05).  All patients and the individuals in the 
control group exhibited tt genotype for TaqI calcitonin gene and no significant association was found 
between these participants and osteoporosis. Conclusion:  There was no association between two 
polymorphisms and osteoporosis, and between polymorphism of these two genes and osteoporosis 
development rate in the participants.
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1. INTRODUCTION
Osteoporosis is a common skeletal 
disorder, accompanied with decrease 
in bone mass, deterioration of bone mi-
crostructures, and increase in suscepti-
bility to fracture (1). Fracture contrib-
utes to increasing morbidity and mor-
tality and imposes high costs on indi-
viduals and community. On average, 
one woman per three and one man per 
12 experience fracture during lifetime 
(2, 3). In the USA, annually 1.5 million 
fractures occur due to osteoporosis. 
More than 50% of these patients could 
not well recover their previous activi-
ties and 10% will need long term ther-
apeutic practices. Deep venous throm-
bosis is high (20-50%) in these patients 
(1, 4).
Bone mass reaches to its maximum 
level in early adulthood and then de-
clines gradually as age advances. In 
women, particularly postmenopausal, 
as estrogen decreases, intestinal and 
renal calcium absorption decreases and 
calcium intake by the bones reaches to 
its minimum level. Therefore, post-
menopausal estrogen decline is one 
of the predisposing factors for osteo-
porosis in postmenopausal women (2, 
5). Genetic differences could also con-
tribute to the variety of contents in 
bone minerals in different ethnics (6).
Calcitonin is a polypeptide hormone, 
comprising 32 amino acids and contrib-
uting mainly to calcium concentration 
regulation. This hormone is secreted 
by parafollicular C cells of mamma-
lian thymus and thyroid. A disulfide 
bond links cysteine 1 to cysteine 7 and a 
7-amino acid circular structure is devel-
oped at the end of amine. Precursor of 
pre-procalcitonin has 141 amino acids. 
Calcitonin gene is located on short arm 
of chromosome 11 (11p15) (7, 8, 9).
Calcitonin declines the cells’ permea-
bility toward calcium, stops osteoclasts’ 
activity, and facilitates and intensifies 
osteogenesis through stopping calci-
um’s intake from bones and intensi-
fying osteoclastic activities. As a result, 
the blood’s calcium and phosphate de-
cline, which causes decline in hydroxy-
proline of the blood and urine (7, 8).
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Hopner et al. found that calcitonin gene (CT) holds a poly-
morphic site for TaqI restriction enzyme, this site is located 
on short arm of chromosome 11, and this polymorphism is 
associated with several diseases. In this gene, there is another 
polymorphism called dinucleotide repeat calcitonin, which is 
associated with bone density rate (9, 19). Miyao et al. inves-
tigated the association between the dinucleotide repeat calci-
tonin in calcitonin polymorphism locus in Japan (9).
Calcitonin receptor is the receptor of calcitonin hormone. 
Calcitonin receptor gene (CTR) is located on long arm of 
chromosome 7 (7q21). This receptor exists in osteoclasts, 
renal tract epithelium, testicles, brain, and ovary. Calcitonin 
activity is mediated through high-affinity receptor, i.e. calci-
tonin receptor (11, 12).
Calcitonin receptor gene has also polymorphism TaqI 
which is associated with bone density rate. Masi et al. indi-
cated that this polymorphism was associated with bone den-
sity rate and the individuals with genotype tt had a less bone 
density compared with the heterozygous Tt individuals (13).
In calcitonin and calcitonin receptor genes, the ability to 
develop cutting by the enzymes TaqI and AluI causes devel-
opment of the following genotypes: AluI genotypes CC, TC 
and TT (14, 15) and TaqI genotypes TT, Tt and tt (16).
The main purpose in treating osteoporosis is to prevent 
fractures. Recent advances in detecting genetic basis of dis-
eases have opened new horizons. Disease diagnosis through 
genotype determination is increasing. The pharmacologic 
and interventional methods available for preventing oste-
oporosis in the individuals at risk add to the significance of 
the issue. Also, no study has been yet conducted on the asso-
ciation between molecular basis of bone density decline and 
the polymorphisms AluI calcitonin receptor in Iran. There-
fore, this study was conducted to investigate the association 
between AluI (rs1801197) calcitonin receptor gene and bone 
density rate in 45- and above 45-year-old women in south-
western Iran.
2. MATERIALS AND METHODS
In this descriptive, analytical study conducted between 
December, 2012 and September, 2013. This research was ap-
proved at research at council and ethics committee of Shahre-
kord University of medical Sciences-Iran. Ethics code: 92-
12-17. sample size was calculated by Cochrane equation. 45- 
and over 45-year-old women referring the centers for bone 
density measurement in southwestern Iran were enrolled 
based on convenience sampling after the consent to partici-
pate in the study was obtained. The questionnaires of clin-
ical and demographic data were filled out. Exclusion criteria 
were corticosteroids consumption history, ovariectomy or 
premature ovarian failure, thyroid disease, calcium intake 
disorders, gastrointestinal and renal diseases, etc. Bone den-
sity rate in lumbar vertebrae and femoral neck was measured 
using dual-energy X-ray absorptiometry (DEXA) and the 
values were determined by t-score. A 5-ml peripheral blood 
was taken from each patient in the tubes containing EDTA 
(0.5 M). DNA was extracted using phenol-chloroform for 
molecular experimentations (17). Quality and quantity of the 
extracted DNA were examined by spectrophotometry using 
Nanodrop.
Sequence of calcitonin and calcitonin receptor genes was 
extracted from NCBI database. The primers for the poly-
morphism AluI and TaqI were designed using online Primer3 
software. The used primers are shown in Table 1.
Amplification of fragments containing TaqI calcitonin 
gene and AluI calcitonin receptor gene polymorphisms was 
done by PCR. Investigation of PCR products and deter-
mination of the genotypes were done using electrophoresis 
technique on polyacrylamide gel 8% by means of Tris-Borate 
EDTA (TBE) and loading 6X (Fermentas) buffers (18).
In each PCR, a vial was considered as negative control to 
show no contamination with DNA sample. The final volume 
of the reaction mixture was determined 25 µl per each mi-
cro-tube were considered. Thermocycler (PC818, ASTEC, 
Japan) was used.
The fragments were treated using restriction enzymes of 
AluI and TaqI (Fermentas). The marker of DNA size used was 
GeneRulerTM DNA Ladder, ready-to-use. For observing the 
obtained bands, silver nitrate staining was used.
Restriction fragment length polymorphism (RFLP): 
RFLP is a method based on longitudinal study of differences 
in a specific fragment of DNA that is highly capable of de-
tecting some loci. Three cutting enzymes of AluI and Taq1 
(Fermentase, Germany) were used for RFLP. For this pur-
pose, a mixture containing 10 ml of PCR product, 1 µl of 
AluI and Taq1, and 2 µl of each enzyme buffer was prepared 
in a final volume of 30 µl and incubated for 16 h at 37°C. Re-
striction digestion products obtained in the acrylamide gel 
were electrophoresed and stained using silver nitrate.
In this study, t-score > − 1 was determined as normal, 
t-score ≤ − 1 to ≥ − 2 as mild osteopenia, t-score < − 2 to ≥ − 
2.5 as severe osteopenia, and t-score < − 2.5 as osteoporosis 
(19).
The data were analyzed by SPSS software using chi-square 
and ANOVA. The association between different genotypes 
of the polymorphisms and bone density rate was investigated 
by ANOVA. The CI in all experiments was considered 95% 
and P<0.05 was considered significant.
3. RESULTS
Since all women over 45 years old have some bone density 
decline, we assigned, based on radiographs’ t-scores, the in-
dividuals with normal bone density and/or mild osteopenia 
as the control group (70 individuals) and those with severe 
osteopenia and osteoporosis as the patient group (130 indi-
viduals) (Table 2).
The quality of the extracted DNA samples was mostly de-
sirable and A260/A280 between 1.75 and 2. The size of frag-
ments obtained from PCR in the polymorphism TaqI calci-
tonin gene was 280 bp which produced two 111 and 169-bp 
fragments after digestion by enzyme TaqI, if the detection 
site of the enzyme was present. In addition, the length of am-
5 -´3´ Primer sequences Primer type Polymorphism type
ATTCAGTGGAACCAGCGTTGG F AluI
CTCAGTGATCACGATGCTGTG R AluI
CAGACTGTGCATGCTACA F Taq1
CCTGCCTGCAACAGGAC R Taq1
Table 1. The sequence of used primers in the study
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plified fragment in the polymorphism AluI of receptor calci-
tonin gene was 228 bp which produced two 108 and 120-bp 
fragments after digestion by enzyme AluI, if the restriction 
site of the enzyme was present (Figures 1,2).
Genotypic frequency was calculated for the polymor-
phisms in the two groups (Tables 3-4). For polymorphism 
AluI in both groups, degree of freedom (df) was considered 2 
and p value was obtained > 0.05 (P = 0.16 in the control group 
and P = 0.443 in the patients); that is, there was no statisti-
cally significant deviation for the polymorphism AluI and 
Hardy-Weinberg equilibrium was noted.
Mean t-score for lumbar vertebrae was–2.933 in the partic-
ipants with genotype TT,–2.819 in those with genotype CC, 
and–2.712 in those with genotype TC. df for both lumbar 
vertebrae and femoral neck was 2 and P value for lumbar ver-
tebrae 0.466 and that of femoral neck 0.959, indicating that 
the polymorphism AluI was not significantly associated with 
t-score, i.e. bone density.
It is noteworthy that for TaqI all individuals in both groups 
had the geno6type tt, such analyses were not done for this 
restriction site and its possible association with bone density.
4. DISCUSSION
Osteoporosis is one of the most prevalent metabolic dis-
orders of bone minerals. This disease is multifactorial and is 
developed by interaction among environmental factors, dif-
ferent genes, and aging. In this study, the association between 
polymorphism TaqI of calcitonin gene and bone density was 
investigated in 45- and above 45-year-old women. In other 
studies, this polymorphism was associated with other dis-
eases, but the association between this polymorphism and os-
teoporosis has not yet been examined. If this polymorphism 
is noted in the individuals with osteoporosis, three genotypes 
are developed. However, the polymorphism of this site, 
throughout the study, was not noted in the osteoporotic indi-
viduals, and all participants had homozygous genotype tt and 
cutting site was not polymorphic.
Also, in the present study, existence of two allelic forms of 
calcitonin receptor gene was confirmed due to polyphormi-
stic site of AluI. We found that genotypic frequency of het-
erozygous TC individuals in the patients was higher com-
pared with other genotypes. We also found that heterozy-
gous TC individuals had a higher bone density compared 
with other genotypes. Therefore, heterozygot genotype of 
calcitonin receptor gene is more frequent than other hemo-
zygot genotypes. Homozygous TT individuals had a lower 
bone density compared with homozygous CC. However, 
there was generally no significant association between bone 
density and no statistically considerable difference in geno-
typic distribution and allelic frequency between the patients 
and the control group.
Several studies have been conducted on association be-
tween several genes polymorphisms and osteoporosis, in-
cluding vitamin D receptor gene, collagen Type 1, calcitonin 
receptor, growth factor, insulin-like, interleukin 6, etc (20).
Variable Mean ± SD 
*
(Patient group)
Mean ± SD
(Control group) P-Value
Lumbar vertebrae’s 
T-score - 2.8 ± 0.67 - 0.9 ± 0.8 < 0.0001
Femoral neck’s T-score - 1.3 ± 0.78 - 0.34 ± 0.5 < 0.0001
Age (year) 59.9 ± 8.4 51.3 ± 5.7 < 0.0001
Height (cm) 154.8 ± 3.6 158.5 ± 4.9 < 0.0001
Weight (kg) 66.3 ± 8.09 71.7 ± 9.1 < 0.0001
Lumbar vertebrae’s 
BMD * (g/cm2) 0.73 ± 0.1 0.92 ± 0.15 < 0.0001
Femoral neck’s BMD 
(g/cm2) 0.76 ± 0.1 0.88 ± 0.11 < 0.0001
Table 2. Characteristics of control and patient groups under study. , * 
Bone mineral densityThe number of patient group is 130 and control 
group is 70.
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9- Figures: 
Figure 1. 
 
A: PCR product of polymorphism AluI (The size of amplified fragment was 228 bp); B: 
Enzymatic dissolution of polymorphism AluI (L: DNA ladder. The samples 2, 3, 4, 7-12 
had three 228, 108, and 120-bp bands [genotype TC], Sample1 has two 228-bp bands 
[the individuals with homozygous genotype CC], and samples 5 and 6 had two 108- and 
120-bp fragments [genotype TT]). 
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Figure 1. A: PCR product of polymorphism AluI (The size of amplified 
fragment was 228 bp); B: Enzymatic dissolution of polymorphism 
AluI (L: DNA ladder. The samples 2, 3, 4, 7-12 had three 228, 108, and 
120-bp bands [genotype TC], Sample1 has two 228-bp bands [the 
individuals with homozygous genotype CC], and samples 5 and 6 had 
two 108- and 120-bp fragments [genotype TT]).
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Figure 2. 
 
A: The product of polymorphism TaqI PCR (the size of amplified fragments was 280 
bp). B: Enzymatic dissolution of polymorphism TaqI (All individuals in case and 
control groups had genotype tt). 
Figur  2. A: The roduct of polymorphism TaqI PCR (the siz  of 
amplified fragments was 280 bp). B: Enzymatic dissolution of 
polymorphism TaqI (All individuals in case and control groups had 
genotype tt).
Polymorphism type
Genoytpic frequency
genotype Control group Patient group
AluI calcitonin re-
ceptor gene polymor-
phism
TT 22 (31.4%) 33 (25.4%)
TC 27 (38.6%) 72 (55.4%)
CC 21 (30%) 25 (19.2%)
total 70 (100) 130 (100%)
TaqI calcitonin gene 
polymorphism
tt 70 (100%) 130 (100)
total 70 (100%) 130 (100)
Table 3. The genotypic number and percent of polymorphisms in the 
two groups
Polymorphism type Control group Patient group
AluI calci-
tonin re-
ceptor gene 
polymor-
phism
geno-
type
The ob-
served in-
dividuals
The ex-
pected in-
dividuals
The ob-
served in-
dividuals
The ex-
pected in-
dividuals
TT 22 18.2 33 36.5
Tc 27 35 72 64.8
cc 21 16.8 25 28.7
total 70 70 130 130
Table 4. The number of expected and observed individuals for 
polymorphism AluI in the two groups
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Nakamura et al. in a study in Japan found an RFLP in cal-
citonin receptor gene nucleotide 1377 which caused substitu-
tion of a leucine amino acid in 463 site with proline. The gen-
otype of heterozygous individuals is manifested as TC, leucin 
hemozygpus individuals as TT, and homozygous proline as 
CC (21). Lack of the remaining proline could change the 
second structure of calcitonin receptor. This change could 
decrease calcitonin hormone bond to calcitonin receptor gene 
and adenylate cyclase response decreases. Therefore, C do-
main of calcitonin receptor terminal is especially important. 
Heterozygous genotype or proline/leucine existence changes 
calcitonin receptor biological activity. Since individuals 
with heterozygous genotypes produce both alleles, they are 
somehow superior over other homozygous genotypes.
Some researchers found similar results. For example, Massi 
et al. in Italy found that frequency of heterozygous TC and 
homozygous TT genotypes was high. Also, homozygot TT 
genotype decreased lumbar bone mineral density (BMD) 
considerably compared with the genotype CC (Masi, 1998). 
In Taboulet et al. study, femoral neck’s BMD was higher con-
siderably in heterozygous TC individuals compared with ho-
mozygous leucine TT and homozygous proline CC. Fracture 
risk also was lower in heterozygous individuals (22).
In a study in Turkey, no statistically significant difference 
was found in genotype and allelic frequency between the pa-
tients and the control group (23), which is consistent with the 
present study. Braga et al. found that polymorphism AluI cal-
citonin receptor gene in lower ages was associated with ver-
tebral column BMD. That is, this polymorphism was more 
correlated with bone mass compared with bone loss due to 
aging (24), which is in contrast to our study. In addition, Tsai, 
in a study in Taiwan, found that this polymorphism was asso-
ciated with osteoporosis prevalence and the individuals with 
the genotype TT were at high risk of osteoporosis in lumbar 
vertebrae and femoral neck (25). In Drews et al. study, BMD 
was very high in heterozygous individuals and this polymor-
phism was associated with osteopenia and osteoporosis prog-
ress (Drews, 2005). In two studies in Korea and Spain, the 
polymorphism AluI and BMD were associated (26, 27). In 
addition, in Charopoulos study, this polymorphism was asso-
ciated with brachial BMD (28).
However, study of the association between several poly-
morphic sites of vitamin D receptor and bone density has re-
vealed different findings worldwide. Liu et al. argued that 
polymorphism TaqI vitamin D receptor was far unlikely to 
be associated with body mass index variations, but could be 
only an indicator in a strong, unbalanced link with a close 
functional mutation (29). Mitra et al. study of the polymor-
phisms of vitamin D receptor (Apa1, TaqI, Fok1, Bsm1) and 
bone density in Indian postmenopausal women indicated that 
individuals with the genotypes aa, FF, and TT had a higher 
bone density compared with the genotypes AA, BB, ff, and 
tt (30). Zhang et al. did not observe any significant associ-
ation between different polymorphisms of vitamin D genes 
and bone density in postmenopausal period (31). However, in 
some studies, polymorphism TaqI was associated with BMD 
in femoral neck and lumbar neck (7, 27). This inconsistency 
of the findings could be due to the difference in sample size 
or inadequate number of the samples, as well as racial differ-
ences among different communities. However, the important 
finding in the present study and other studies is higher bone 
density in the individuals with heterozygous TC genotype of 
calcitonin receptor gene compared with homozygous geno-
types.
5. CONCLUSION
This study indicated no statistically significant deviation 
for polymorphism TaqI, AluI gene, and calcitonin receptor in 
the patients and control group. In this study, we used RFLP 
method to make the findings consistent with those of other 
studies conducted on this field. The association between 
other polymorphisms involved in osteogenesis regulation 
and bone density should be studied. Also, further research is 
recommended to study calcitonin gene TaqI polymorphism.
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